NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2025. SO WHAT: If you purchased Humacyte securities during the Class P ...

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, inclusive. For more information, submit a form at Humacyte, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (2 ...

SAN FRANCISCO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v. Humacyte, Inc., et al., alleges that the company misled investors about the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel (ATEV) and the regulatory compliance of its manufacturing facilities. Hagens Berman urges in ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Nov. 21, 2024 /PRNewswire/ ...

NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2025.So What: So what: If you purchased Humacyte securities during the Class Per ...

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of all persons or entities who purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 through October 17, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the fe ...

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investo ...

SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations:  ...

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte secur ...

文章核心观点 - 针对Humacyte公司提起股东集体诉讼 诉讼称被告存在虚假误导性陈述或未披露重大不利事实 [1] - 鼓励在2024年5月10日至2024年10月17日期间购买公司股票且遭受重大损失者联系律师商讨法律权利 [2] - 2025年1月17日为申请成为主要原告的截止日期 [3] 诉讼相关指控 - 公司北卡罗来纳州达勒姆工厂未遵守良好生产规范包括质量保证和微生物检测 [1] - 公司补救这些缺陷期间FDA对生物制品许可申请的审查将被推迟 [1] - 因此无细胞组织工程血管（ATEV）获得FDA批准存在重大风险 [1] 投资者相关 - 若在特定期间购买公司股票且遭受重大损失可联系Corey D. Holzer律师商讨法律权利 可通过cholzer@holzerlaw.com邮箱 免费电话(888) 508 - 6832或访问公司网站www.holzerlaw.com/case/humacyte/了解更多 [2] - 2025年1月17日为申请成为案件主要原告的截止日期 [3] 律师事务所相关 - Holzer & Holzer LLC为ISS 2021 2022 2023年顶级评级证券诉讼律师事务所 致力于在全国范围内积极代表股东和投资者进行诉讼包括股东集体诉讼和派生诉讼 [3] - 自2000年成立以来 该事务所律师在为受欺诈和其他公司不当行为侵害的股东追回数亿美元方面发挥了关键作用 [3] - 可通过网站www.holzerlaw.com获取更多事务所信息 也可向事务所提出请求 [3] - 由Corey Holzer负责此次宣传内容 [3] 联系方式 - 可联系Corey Holzer律师 免费电话(888) 508 - 6832 邮箱cholzer@holzerlaw.com [4]